BSR maintains formal coverage on the development-stage biotechnology companies listed below. Having a company in our coverage universe does not necessarily mean we see them as a good investment. Our opinions on the companies appearing below range from a belief they should be overweight in a diversified biotechnology portfolio to a determination they are not suitable for investment capital. Clicking on the name of the company takes you to brief summary and a link to everything we've published on the company.

Company	Ticker	First coverage
ARyX Therapeutics	ARYX	June 2009
BioMarin Pharmaceuticals	BMRN	October 2004
Cell Therapeutics	CTIC	March 2010
Corcept Therapeutics	CORT	September 2004
Dendreon	DNDN	February 2001
Dynavax	DVAX	July 2006
ImmunoGen	IMGN	October 2009
Inovio	INO	July 2009
Oncolytics Biotech	ONCY	June 2005
GenMark Diagnostics (fka Osmetech)	GNMK	February 2008
PolyMedix	PYMX	January 2009
Raptor Pharmaceuticals	RPTP	July 2008
Repros Therapeutics	RPRX	February 2006
Resverlogix	TSE:RVX	January 2008
SciClone Pharma	SCLN	April 2003
Seattle Genetics	SGEN	June 2002
YM Biosciences	YMI	November 2005
ZymoGenetics	ZGEN	November 2002